Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios

References

• Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al.: AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358–380, 2018.
   PubMed Web of Science ®Google Scholar
• World Health Organization. GLOBOCAN Cancer Fact Sheets: liver Cancers. Available at: http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp. Accessed on June 27, 2018.
   Google Scholar
• Bruix J, Reig M, and Sherman M: Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150, 835–853, 2016.
   PubMed Web of Science ®Google Scholar
• D'Amico G, Garcia-Tsao G, and Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44, 217–231, 2006.
   PubMed Web of Science ®Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60, 646–649, 1973.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ; Cirrhosis Asian Lamivudine Multicentre Study Group, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351, 1521–1531, 2004.
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, et al.: Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol 32, 1982–1988, 2017.
   PubMed Web of Science ®Google Scholar
• Morgan MY, Marshall AW, Milsom JP, and Sherlock S: Plasma amino-acid patterns in liver disease. Gut 23, 362–370, 1982.
   PubMed Web of Science ®Google Scholar
• Soeters PB and Fischer JE: Insulin, glucagon, aminoacid imbalance, and hepatic encephalopathy. Lancet 2, 880–882, 1976.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Maekawa M, Kuwabara Y, Nakajima T, Taniguchi K, et al.: Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatic diseases, and its clinical usefulness. Clin Chem 35, 1399–1403, 1989.
   PubMed Web of Science ®Google Scholar
• Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, et al.: Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 313, 405–409, 2004.
   PubMed Web of Science ®Google Scholar
• Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Long-Term Survival Study Group, et al.: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3, 705–713, 2005.
   PubMed Web of Science ®Google Scholar
• Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K; Long-Term Survival Study (LOTUS) Group, et al.: Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 35, 204–214, 2006.
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, et al.: Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis. Hepatol Res 44, 288–295, 2014.
   PubMed Web of Science ®Google Scholar
• Bruix J and Sherman M: American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020–1022, 2011.
   PubMed Web of Science ®Google Scholar
• Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, et al.: Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int 33, 327–337, 2013.
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, et al.: On behalf of the Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 3, 458–468, 2014.
   PubMed Web of Science ®Google Scholar
• Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, et al.: HCC expert panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29, 339–364, 2011.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1992.
   Google Scholar
• Guilford JP: Fundamental Statistics in Psychology and Education. New York: McGraw Hill, 1956.
   Google Scholar
• Fine JP and Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94, 496–509, 1999.
   Web of Science ®Google Scholar
• Belghiti J, Panis Y, Farges O, Benhamou JP, and Fekete F: Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214, 114–117, 1991.
   PubMed Web of Science ®Google Scholar
• Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48, 452–458, 2013.
   PubMed Web of Science ®Google Scholar
• Mizuguchi T, Kawamoto M, Meguro M, Nakamura Y, Harada K, et al.: Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg 15, 1433–1439, 2011.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Kubota T, Horigome R, Kimura N, Honda H, et al.: Branched-chain amino acids to tyrosine ratio (BTR) predicts intrahepatic distant recurrence and survival for early hepatocellular carcinoma. Hepatogastroenterology 60, 2055–2059, 2013.
   PubMedGoogle Scholar
• Ishikawa T, Imai M, Ko M, Sato H, Nozawa Y, et al.: Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis. Oncotarget 8, 79480–79490, 2017.
   PubMedGoogle Scholar
• Nishikawa H, Osaki Y, Iguchi E, Koshikawa Y, Ako S, et al.: The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 47, 359–366, 2013.
   PubMed Web of Science ®Google Scholar
• Murata K and Moriyama M: Isoleucine, an essential amino acid, prevents liver metastases of colon cancer by antiangiogenesis. Cancer Res 67, 3263–3268, 2007.
   PubMed Web of Science ®Google Scholar
• Ohno T, Tanaka Y, Sugauchi F, Orito E, Hasegawa I, et al.: Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis. Hepatol Res 38, 638–683, 2008.
   PubMed Web of Science ®Google Scholar
• Nakamura I, Ochiai K, Imai Y, Moriyasu F, and Imawari M: Restoration of innate host defense responses by oral supplementation of branched-chain amino acids in decompensated cirrhotic patients. Hepatol Res 37, 1062–1067, 2007.
   PubMed Web of Science ®Google Scholar
• Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, et al.: ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 25, 285–294, 2006.
   PubMed Web of Science ®Google Scholar